INTRODUCTION
Rheumatoid Arthritis (RA) is a chronic autoimmune disease affecting synovial joints that can lead to severe disability. Pivotal pathophysiological insight has been obtained by the identification of Anti-Citrullinated Protein Antibodies (ACPA) [1, 2] . These autoantibodies target proteins that have undergone a post-translational conversion of arginine to citrulline, catalyzed by peptidylarginine deiminases (PAD enzymes) [3] . ACPA are highly specific for RA, enriched in the joints of patients and can cross-react between citrullinated antigens that are expressed in the inflamed joints [4] [5] [6] [7] [8] . It is clear now that RA represents two main syndromes, ACPA-positive and ACPA-negative disease, each with distinct genetic and environmental risk factors and disease outcome [9] [10] [11] [12] . Characteristics of ACPA (e.g. isotype usage and epitope spreading) indicate the involvement of CD4+ T cell help in shaping the ACPA response [13] . The most important genetic risk factor for ACPA+ RA is the HLA class II locus and risk is confined to a region with genes encoding for the beta chain of HLA-DR and the alpha and beta chain of HLA-DQ that are in tight linkage disequilibrium (LD) and inherit in haplotypes [14, 15] . An understanding of the HLA class II association and the relative contribution of the HLA-DR and HLA-DQ locus has been lacking for the last 35 years. Next to the association of the predisposing alleles to ACPA-positive disease, other HLA-molecules are associated with protection. These protective HLA alleles, mainly HLA-DRB1*13, carry the five amino acid sequence DERAA at positions 70-74 of the beta chain and protect also in the presence of predisposing alleles [16, 17] . Intriguingly, protection by these alleles is transferred from mother to child, supporting an active protective role of these alleles, possibly via microchimeric cells influencing thymic selection of CD4+ T cells, and indicating a dominant role of HLA-DRB1*13 in disease protection [18] . HLA-derived peptides are a dominant peptide source presented by HLA class II molecules. We therefore proposed that the protective effect of HLA-DRB1*13 is explained by presentation of an HLA-DRB1*13 derived peptide in the context of other (predisposing) HLA class II molecules [19] [20] [21] . It was previously shown that degradation of HLA-DRB1*13 can result in the presentation of a peptide with the core sequence DERAA by other HLA class II molecules to CD4+ T cells [22] . This could allow for the negative selection of such "DERAA directed" CD4+ thymocytes. Interestingly, the DERAA sequence is also found in many microbes and in the self-protein vinculin. Vinculin is expressed in the synovium, and was recently shown to be citrullinated in the synovial fluid of an RA patient [4, 23] . Likewise, T cells directed to vinculin are found under certain infectious conditions, indicating that T cell tolerance to vinculin is not absolute [24, 25] . Molecular mimicry of self-proteins with pathogenic proteins was proposed as an important mechanism to break T cell tolerance [26, 27] . Therefore, we postulate that upon priming (DRB1*01:01;DQA1*01:02; DQB1*05:01) and 721.82 (DR/DQ-negative). Cells were maintained in IMDM (Lonza) supplemented with 10% heat-inactivated FCS.
HLA class II competitive peptide binding assay
Peptide-binding assays were performed, as described previously [29] . In short, cell lysates from HLA-class II homozygous B-lymphoblastoid cell lines were incubated on SPV-L3-(anti-HLA-DQ) or B8.11.2-(anti-HLA-DR) coated (10 μg/ml) FluoroNunc 96-well plates at 40C overnight. Titration ranges of the tested peptides (0 to 300 μM) were mixed with a fixed concentration (0.6 μM) of biotinylated indicator peptide and added to the wells. Bound indicator peptide was detected using europium-streptavidin (Perkin Elmer, Boston, MA) and measured in a time-resolved fluorometer (PerkinElmer, Wallac Victor2). IC50 values were calculated based upon the observed binding of the test peptide against the fixed concentration indicator peptide. The IC50 value depicts the concentration of test peptide required for a loss of 50% of the indicator peptide signal.
Enzyme-linked immunosorbent spot assay
PBMCs were incubated in 96-well Multiscreen HA plates (Millipore) precoated with 5 μg/ml anti-IFN-γ capture antibody (clone 1-D1K; Mabtech) at 5x10 5 cells/well and stimulated in X-VIVO medium (LONZA) with 5 μg/ml peptide or with a mix of recall antigens consisting of 0.75 Lf/ml tetanus toxoid (Netherlands Vaccine Institute), 0.5 μg/mL tuberculin purified protein derivative (Netherlands Vaccine Institute) and 0.005% Candida albicans (HAL allergy). After 24h incubation at 37ºC, plates were extensively washed and incubated with 0.3 μg/ml biotin labeled anti-IFN-γ detection antibody (clone 7-B6-1; Mabtech) for 2h at RT, with 1000x diluted ExtrAvidin-Alkaline phosphatase (Sigma-Aldrich) for 1h at RT and with 5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue tetrazolium (Sigma-Aldrich). Spots were analyzed using the BioSys Bioreader 3000pro. Circular spots with a size of 80-450μm were included.
Flow cytometry
Polyclonal CD4+ T cell lines were generated by stimulating 3 x 10 6 PBMCs/well in a 24-well plate with 5 μg/ml peptide for 7 days in IMDM supplemented with 5% human serum (Sanguin). After 7 days 1.5 x 10 6 autologous PBMCs per well were plated in 24-well plates for 2h. After 2h non-adherent cells were removed and adherent cells were pulsed with 5 μg/ml peptide and used as feeders for 106 T cells. After 1h, 10 μg/ml brefeldin A was added. Cells were incubated overnight and used for intracellular cytokine staining. The cells were incubated with fluorochrome-conjugated antibodies recognizing CD4, (Clone RPA-T4; BD biosciences), CD14 (Clone 61D3; eBioscience) and CD25 (Clone M-A251; BD biosciences), after which they were permeabilized using CytoFix CytoPerm Kit (BD Biosciences). After washing, cells were incubated with PE-labeled anti-IFN-γ or matching isotype control. Cells were taken up in 1% paraformaldehyde until flow cytometric acquisition. Flow cytometry was performed on FACS Calibur (BD biosciences) or LSR II (BD biosciences). Analysis was performed using FACS Diva (BD biosciences) and FlowJo software.
T cell cloning JPT57 was generated from an HLA-DRB1*04:05/01:01;DQ8/DQ5 donor. PBMCs were cultured for 7 days in the presence of 10 μg/ml of VCL-DERAA peptide and restimulated with VCL-DERAA-pulsed antigen-presenting cells. After 1 week, cells were restimulated with 150 U/ml rIL-2. After two rounds of restimulation, T cell lines were tested for their specificity. The wells responding to VCL-DERAA peptide were cloned in a limiting dilution of 0.3 cells/well resulting in the isolation of clone JPT57. D2C18 was generated from an HLA-DRB1*04:01;DQ2/DQ8 positive donor. CD4+ T cells and CD14+ monocytes were isolated from PBMCs using antibodies bound to magnetic beads from respectively Dynal and Miltenyi. CD4+ T cells were labeled with 1μM CFSE (Invitrogen) and incubated in a 2:1 ratio with CD14+ monocytes with 30 μg/ml PathMix. After 6 days, CD3 pos CD4 pos CD25 pos CD14 neg DAPI neg CFSE low cells were sorted by FACS aria (BD). Isolated CD4+ T cells were rested in medium containing 20 IU/ml rIL-2 (Peprotech). After 3 days, cells were cloned in a limiting dilution of 0.3 cells/well resulting in the isolation of CD4+ T cell clone D2C18.
T cell activation
To determine IFN-γ production by T cell clones in response to peptide stimulation, 50.000 T cells were incubated in a 1:1 ratio with B-LCL lines pulsed with 10 μg/ ml of peptide for 3-6h. After 3 days, supernatant was collected and an IFN-γ ELISA (eBioscience) was used to determine the concentration of IFN-γ. For measurement of T cell proliferation, 50.000 T cells were incubated in a 1:1 ratio with radiated (3000RAD) autologous PBMCs pulsed with 10 μg/ml of peptide for 3-6h in IMDM supplemented with 5% human serum. After 3 days, cells were cultured for 16-20h with [ 3 H]thymidine (0.5 μCi/well). 3 H incorporation was measured by liquid scintillation counting (1450 MicroBeta TriLux; PerkinElmer). Blocking experiments were performed by preincubating APCs for 1h with anti-DQ (SPVL3), anti-DR (B8.11.2) and anti-DP (B7.21) blocking antibodies.
Detection of anti-citrullinated vinculin antibodies
Citrullinated vinculin was generated by incubation of 50 μg vinculin protein (Sanbio) in a volume of 200 μl containing 0.1 M Tris-HCl pH 7.6, 0.15 M CaCl 2 , and 10 U PAD4 (Sigma) for 4 h at 37 °C. Unmodified vinculin-protein was generated by incubation of vinculin with PAD4 without CaCl 2 . Citrullinated and unmodified vinculin were loaded onto 10% SDS-polyacrylamide gels and transferred onto blotting membranes. Blots were blocked, washed and incubated in 1:500 diluted serum overnight at 4°C. The sera were either ACPA-positive or ACPA-negative as determined by ELISA. Blots were incubated with HRP-labeled rabbit anti-human IgG (Dako) and visualized with chemiluminescence (ECL, Amersham). To analyze reactivity to vinculin by a monoclonal ACPA (anti-cFIB1.1, citrullinated fibrinogen), vinculin-or citrullinated vinculin-coated Nunc plates were incubated with 5 μg/ml anti-cFIB1.1 for 2h at room temperature [30] . Bound antibody was detected using HRP-labeled rabbit anti-human IgG (Dako) and visualized with ABTS. Peptide-ELISA was performed as described previously using biotinylated peptides coated on streptavidin precoated plates [31] .
B cell activation by JPT57 cells
B cells were isolated from PBMCs of HLA-DQ8 positive healthy donors or ACPA positive RA patients by magnetic anti-CD19 beads (Invitrogen). B cells were cultured in IMDM supplemented with 10% FCS, penicillin, streptomycin and glutamax. From healthy subjects, 30,000 B cells were co-cultured with different number of JPT57 cells in the presence of 5μg/ml anti-IgM (JacksonImmunoresearch Laboratories) and with 10 μg/ml VCL-DERAA or 1 μg/ml PHA in round-bottom 96-well plates. After 7 days, IgG production by B cells was determined using a total IgG ELISA (Bethyl laboratories). From RA patients, 20,000 B cells were pulsed with 10 μg/ml VCL-DERAA peptide and co-cultured with 20,000 JPT57 cells in the presence of 5 μg/ml anti-IgM in round-bottom 96-well plates. After 7 days, ACPA production was determined by ELISA measuring reactivity against the CCP2-peptide in individual wells (EuroDiagnostica).
Energy minimization
Molecular simulations of HLA-DQ8(A1*0301/B1*302) and -DQ7.3 (A1*0302/ B1*0301) complexed with various peptides, experimentally shown to bind to these molecules, were carried out as previously described using the Discover Suite (programmes InsightII and Discover) of Accelrys (San Diego, CA, release of 2005) on a Silicon Graphics Fuel instrument, using a minimization approach previously described [32] , i.e. one thousand steps of the steepest gradient method, followed by one thousand steps of the conjugate gradient method. Records of the energy of every step showed a continuous decrease in energy without any local minima and an energy asymptote for the last 300-400 steps of the conjugate gradient method. The base molecule was the crystal structure of HLA-DQ8 (A1*0301/B1*0302) with bound the insulin B11-23 peptide [33] . The region HLA-DQβ105-112 for which full coordinates were not available in the original data, was constructed by molecular replacement of the respective region from HLA-DR1 [34] , after superposition of the β-plated sheet regions of the two molecules in the α1β1 domains. The binding registers of the vinculin and the bound microbial peptides were decided from the binding of truncated peptides as well as Arg-substituted peptides in presumed anchor positions; energy minimization of successive registers confirmed the registers predicted from the binding data. The rotamers for the peptide residues were chosen from a library of rotamers provided by the software data base, in order to have no molecular clashes with the residues of HLA-DQ8. Minimizations were carried out either at pH 5.4 (endosomal pH) or 7.4 (extracellular). There are no similarly charged residues (e.g. Glu-Glu) with their charged groups so close to each other as to require that one of the residues be uncharged. Occasionally runs were performed on a Silicon Graphics Octane instrument with previous releases of the same software with very similar results. level of the peptide backbone and parallel to the HLA-DQ β-sheet floor is visualized with atomic charges coloured accordingly (red, acidic; blue basic, and with appropriate scales of grey for cases in between). In the supplementary figures, the α1β1 domains of the modelled HLA-DQ molecules in complex with given bound peptides are depicted in van der Waals surface representation, with color and depiction conventions identical to those for the other figures. Several visible residues from the HLA-DQ molecule in contact with the antigenic peptide and potential contact with a cognate TCR in canonical orientation are shown in stick form with a transparent surface (atomic color code: oxygen, red; nitrogen, blue; hydrogen, white; carbon, geen; sulfur, yellow). The antigenic peptide in the groove is shown in space-filling form.
Molecular Dynamics Simulations
The simulated system included the entire DQ8 molecule and the 13-residue peptide with the vinculin sequence Glu-Glu-Val-Phe-Asp-Glu-Arg-Ala-Ala-Asn-Phe-Glu-Asn, placed in a periodically replicated octahedral water box. The simulations were conducted with the molecular mechanics program CHARMM, version c37b2 [35] . The initial coordinates of all protein heavy atoms and the peptide mainchain heavy atoms were taken from the crystallographic structure of the DQ8:insulin complex (PDB entry 1JK8) [33] . The peptide side chain initial conformations were optimized with the program PROTEUS [36] . An additional control simulation studied the DQ8:insulin complex; the initial coordinates of the protein and peptide were taken from the corresponding crystal structure (PDB entry 1JK8) [33] . Protein atomic parameters were taken from the CHARMM36 all-atom force field [37, 38] . The interaction energies of selected peptide -protein residue pairs were computed by post-processing the MD trajectories in the GBSA approximation, as in [39] with the GBSW Generalized Born model [40, 41] .
RESULTS

Citrullinated vinculin is a novel target for ACPA
We speculate that the protective effects of HLA-DRB1*13 on the development of ACPA-positive RA are related to a T cell response reactive to a sequence that is commonly present in the HLA-DRB1*13 molecule, micro-organisms and self-proteins that are targeted by ACPA. Indeed, a 5-amino-acid long HLA-DRB1*13-derived sequence (DERAA) is present in many micro-organisms and a few self-proteins. Of these self-proteins, the citrullinated protein vinculin attracted our attention. Therefore, we first analyzed whether citrullinated vinculin is recognized by ACPA. To this end, we citrullinated vinculin in vitro with PAD enzymes and tested both native and citrullinated vinculin for recognition with serum of an ACPA-positive RA-patient. We observed citrulline-specific recognition of vinculin by serum of an ACPA-positive RA patient, but not with an ACPA-negative patient ( Figure 1A ). We further confirmed that citrullinated vinculin is a target of ACPA using an ACPA monoclonal antibody ( Figure 1B ) [30] . Recently, several reports showed the presence of citrullinated vinculin in the synovial fluid of ACPA+ RA patients. In addition, three sites of in vivo citrullination on this protein were identified: Arg285, Arg622 and Arg823 [4, 23] . When we studied antibody responses to these citrullination sites, we could show recognition by 34% of tested sera from ACPA+ RA patients versus 5% of sera from ACPA-patients ( Figure 1C ). Sera of ACPA+ RA patients are highly (cross-)reactive towards multiple citrullinated antigens. Indeed, when we quantified responses to citrullinated alpha-enolase, fibrinogen, vimentin, and myelin basic protein in patient sera that react to citrullinated vinculin peptides, we could readily demonstrate additional reactivities indicating that ACPA are not exclusively directed against citrullinated vinculin as expected ( Figure 1D ). Together, these data show that citrullinated vinculin is a self-protein recognized by RA autoantibodies in a citrulline-dependent fashion.
Vinculin is an autoantigen recognized by T cells from HLA-DRB1*13-negative donors
We next wished to determine whether the DERAA-sequence from vinculin is recognized by human CD4+ T cells. To this end, PBMCs were stimulated with a 15-mer vinculin-peptide (VCL 622-636 , REEVFDERAANFENH) (VCL-DERAA) for 24h. We observed a clear reactivity towards this epitope as determined in an IFN-γ-ELISPOT-assay ( Figure S1 ). HLA-DRB1*13, especially HLA-DRB1*13:01, is strongly associated with protection against ACPA-positive RA [17] . We hypothesize that HLA-DRB1*13 protects against ACPA-positive disease by affecting the generation of DERAA directed T cells. Therefore, we stratified donors for HLA-DRB1*13:01 status. We observed a striking difference in IFN-γ producing cells depending on HLA-DR-B1*13:01-status. The lack of reactivity in HLA-DRB1*13:01-positive donors was not due to a hampered ability of such donors to respond to T cell antigens as we observed strong response to microbial antigens in both HLA-DRB1*13:01 carriers and non-carriers when stimulated with recall antigens (Figure 2A ). We further confirmed this finding in PBMCs stimulated for 4 days ( Figure S2 ). The differential ability of HLA-DRB1*13:01-positive donors to respond to VCL-DERAA is most likely not due to a general deficiency to present the VCL-DERAA-epitope as these donors were heterozygous and thus expressed other HLA-molecules that could potentially present VCL-DERAA. Nonetheless, to further confirm that HLA-DRB1*13:01 affects the ability to generate VCL-DERAA directed T cell responses, we repeated the experiments in a set-up stratified for HLA using PBMCs from HLA-DRB1*04-, HLA-DRB1*13:01-and HLA-DRB1*04/*13:01 heterozygous donors. A significant reduction in IFN-γ producing cells was observed in both HLA-DRB1*13:01 carriers and DRB1*04/*13:01 heterozygous donors as compared to HLA-DRB1*04 carriers. Again, no difference was observed for recall antigens ( Figure 2B ). These data indicate that the lack of detecting VCL-DERAA directed T cells is not explained by the inability of HLA-DRB1*13 molecules to present VCL-DERAA, but rather the result of a dominant effect associated with the presence of HLA-DRB1*13. Thus, vinculin is an autoantigen recognized by circulating VCL-DERAA directed CD4+ T cells. In HLA-DRB1*13:01 carriers these T cells are absent. This effect, like the protective effects of HLA-DRB1*13:01 on the development of ACPA-positive RA, was present in a dominant fashion, consistent with the notion that HLA-DRB1*13 affects the generation of DERAA directed T cells, possibly during thymic selection.
Presentation of the Vinculin-DERAA epitope is restricted to RA predisposing HLA-DQ molecules HLA-DRB1 alleles predisposing to ACPA-positive RA in the Caucasian population are collectively called HLA shared epitope (SE) alleles [14, 15, 42] . The most common HLA-SE alleles are HLA-DRB1*04:01 and HLA-DRB1*01:01. Using HLA-DR binding assays, we examined the ability of VCL-DERAA to bind to these HLA-molecules, but we could not detect any binding of VCL-DERAA to these alleles ( Figure 3A , Figure  S 3A-B ). The HLA class II region is known for its strong LD. Genes that encode for the HLA-DR-beta chains are inherited in haplotypes with genes that encode for the alpha and beta chain of HLA-DQ. The predisposing HLA-SE alleles are in tight LD with HLA-DQ5 (DQA1*01;DQB1*05:01), HLA-DQ7.3 (DQA1*03:02;DQB1*03:01) and HLA-DQ8 (DQA1*03:01;DQB1*03:02) ( Figure 3B -C). In Figure 3C the distribution of HLA-DQ molecules in SE+ healthy donors is depicted, showing that these donors are HLA-DQ5, HLA-DQ7.3 or HLA-DQ8 positive. We therefore next studied the binding of VCL-DERAA to these HLA-DQ alleles and observed binding of the VCL-DERAA-peptide to HLA-DQ5, DQ7.3 and DQ8 ( Figure 3A , Figure S3C -E). These data indicate that VCL-DERAA can be presented by HLA-DQ molecules in LD with predisposing HLA-SE alleles. To obtain an indication whether the VCL-DERAA can be presented by more HLA molecules, we also studied the ability of additional HLA-DR and HLA-DQ molecules encoded by HLA-haplotypes that protect or have no influence on the development of ACPA-positive RA. We could not detect binding of VCL-DERAA to these HLA class II alleles ( Figure 3A , Figure S3F -K). Likewise, using an IFN-gamma ELISPOT, VCL-DERAA directed T cells were absent in donors negative for predisposing HLA-DQ molecules (data not shown). These data indicate that HLA-DQ-molecules that predispose to ACPA-positive disease present the VCL-DERAA-peptide, whereas the analyzed HLA-DQ and HLA-DR molecules not associated with disease do not present VCL-DERAA.
HLA-DQ restricted recognition of VCL-DERAA by T cells
To further confirm the presence of VCL-DERAA directed T cells and their HLA-restriction, we isolated CD4+ T cell clone JPT57, that was specific for VCL-DERAA. As shown in Figure S4 , this clone proliferated readily and produced large amounts of IFN-γ when stimulated with the VCL-DERAA-peptide. When cultured with B cells from ACPA-positive RA patients pulsed with the VCL-DERAA epitope, the clone not only upregulated CD40L, but also enhanced the production of ACPA in culture, indicating that such T cells have a phenotype compatible with the ability to provide "help" to ACPA producing B cells ( Figure S5 ). To further confirm that HLA-DQ-molecules present the VCL-DERAA-peptide, we stimulated the clone with VCL-DERAA pulsed HLA-typed APCs pre-incubated with HLA class II blocking antibodies ( Figure S6 ). In concordance with the binding studies, anti-HLA-DQ antibodies abrogated T cell recognition. Interestingly, we observed that JPT57 can recognize VCL-DERAA, presented by both HLA-DQ7.3 and HLA-DQ8 suggesting that this this epitope is presented in a similar binding register by these HLA-molecules ( Figure S7 ). Together, HLA-class II presentation and T cell recognition of VCL-DERAA was restricted to HLA-DQ molecules that are associated with RA susceptibility.
Identification of microbe-specific T cells targeting DERAA epitopes
We next investigated the presence of the DERAA sequence in micro-organisms. A Blast search showed that DERAA is found in 66% of bacteria and 12% of viruses ( Figure 4A ). This large number represents a major challenge to identify potential "cross-reactive micro-organisms". To select for relevant micro-organisms, we restricted the search to those micro-organisms that can cause disease or symptoms in humans and are present in the western world. This approach left us with 219 candidate sequences. We then synthesized 8 DERAA-containing peptides from common recall microbes including several bacteria (P. acnes, S enteritidis, B. pertussis, S. aureus) and viruses (measles virus, influenza A and human herpesvirus 7). Interestingly, all of these peptides were presented by HLA-DQ7.3 and DQ8 molecules showing that these HLA molecules can efficiently accommodate both the VCL-DERAA epitope as well as microbe-derived DERAA epitopes ( Figure 4B ).
To determine whether these microbial-derived epitopes are recognized by human T cells, we generated T cell lines by stimulating PBMCs from 3 healthy HLA-DQ8 positive donors for 7 days with a pool of the 8 pathogen-derived peptides (PathMix). Next, we determined the presence of PathMix specific CD4+ IFN-γ producing T cells. As shown in Figure 4C , such T cells were readily detectable. Using limiting dilutions, we isolated T cell clone D2C18, further confirming the presence of "microbial-DERAA-directed" T cells ( Figure S8 ). Next, we also analyzed the presence of "microbial-DERAA directed" T cells by ELISPOT directly ex vivo, allowing the analyses of more donors at higher throughput. Interestingly, PBMCs from HLA-DRB1*13:01 carriers displayed a significantly reduced reaction against these peptides, indicating that the presence of HLA-DRB1*13 also affects the formation of T cell responses against DERAA-epitopes from microbes ( Figure 4D ). Together, these data indicate that HLA-DQ alleles associated with ACPA-positive RA efficiently present both VCL-DERAA and microbe-derived DERAA epitopes and that microbe-specific T cells directed to DERAA epitopes are readily detected. The presence of HLA-DRB1*13:01 affects the formation of these T cell-responses. 
Molecular modelling of HLA-DQ:VCL-DERAA complexes allows for predicting cross-eactive microbes
The data presented above demonstrate the presence of microbial-and VCL-DERAA directed T cells, but do not show if a single TCR can react with both epitopes. To facilitate the search for possible "crossreactive" DERAA-epitopes out of all microbe-derived DERAA-sequences, we first determined the binding register of VCL-DERAA using HLA class II binding assays with N-and C-terminally truncated and amino-acid substituted VCL-DERAA peptides as detailed in Figure S9 -13.
Together these experiments support VFDERAANF (anchors in bold) as the core binding register for both HLA-DQ7.3 and HLA-DQ8. All-atom molecular dynamics (MD) simulations showed that residues Val625 (P1), Glu628 (P4) and Phe633 (P9) make numberous intermolecular polar and non-polar interactions in the respective pockets. In Figure 5A -F we highlight key intermolecular interactions between the VCL-DERAA epitope and the HLA-DQ8 molecule. A detailed discussion of the MD results and a quantitative assessment of the intermolecular interactions can be found in the supplementary data ( Figure S14-15 and Table S1 ). The MD simulations also indicated that the long protruding side-chains of Glu623 (P-2) Glu624 (P-1), Phe626 (P2), Asp627 (P3), Arg629 (P5), Asn632 (P8), Glu634 (P10) and Asn635 (P11) are exposed to solved and could potentially interact with crossreactive TCRs ( Figure  5G ). Subsequently we also further confirmed the obtained model using a second type of molecular modelling: energy minimization, that further confirmed possible TCR contact residues ( Figure S16-17 ).
To functionally confirm whether a TCR would indeed interact with (some of the) potential TCR contact residues within the VCL-DERAA-peptide, we next determined how the epitope is recognized by the VCL-DERAA-directed T cell clone JPT57. Phe626 (P2) interacts with the JPT57 TCR as its removal results in a large decrease in recognition without affecting HLA-DQ8 binding. (Figure 5H , Figure S11 ). C-terminal truncations resulted in a large decrease in T cell recognition after removal of Glu634 (P10), showing that this residue is also important for JPT57 TCR interaction ( Figure 5I ). Thus, the data obtained using the VCL-DERAA directed T cell clone as a functional read-out, are in line with the HLA binding and molecular modeling studies indicating the sequence VFDERAANFE (anchors in bold) as the minimal epitope required for activation of JPT57. Next, we performed alanine substitutions within the minimal epitope to remove critical TCR interacting residues. Substituting Asn632 (P8) and Phe633 (P9) dramatically impacted T cell recognition, without affecting the binding affinity of VCL-DERAA ( Figure 5J j. k . ) 
TCR crossreactivity between vinculin and bacterial antigens
Identifying microbes that crossreact with vinculin was challenging due to the large number of potential candidates. Therefore, we used the data presented above to determine if a single TCR can crossreact both to DERAA-sequences from microbes and the self-protein vinculin. As we identified the Asn632 and Phe633 at P8 and P9 respectively, as important for JPT57-TCR interactions, we used the molecular modeling to predict which viral and bacterial epitopes are likely to bind to HLA-DQ8 and harbor P8Asn or P9Phe and are thus likely to crossreact with JPT57. From the 15 peptides identified (Table S2 ), three were able to activate JPT57 in a T cell stimulation assay at concentrations similar to those used for the vinculin-peptide. These epitopes were derived from Campylobacter coli, Lactobacillus curvatus and Lactobacillus sakei and cross-reacted with JPT57 in an HLA-DQ dependent manner ( Figure 6A ). Peptide-binding studies revealed that these three peptides bind with an intermediate binding affinity to HLA-DQ7 and HLA-DQ8 ( Figure 6B-C) .Molecular models of these bacterial peptides in HLA-DQ8 illustrate the similarities with VCL-DERAA ( Figure 6D -G, Figure S18-20) . Thus, these data show that the RA susceptibility alleles HLA-DQ7 and HLA-DQ8 can present both VCL-DERAA and related microbe-derived epitopes to T cells and that such T cells can be cross-reactive to vinculin and bacterial epitopes, thereby providing an explanation for the presence of activated self-reactive CD4+ T cells directed to vinculin in peripheral blood.
DISCUSSION
The strong connection between the HLA locus and RA has been known for more than 35 years. The complex HLA class II associations and the diverse ACPA responses in RA patients suggest the presence of multiple etiological pathways. To unravel these pathways, identifying the relevant autoantigens is crucial. We here present evidence favouring the involvement of vinculin in the emergence of ACPA-positive disease. This cytoskeletal protein was recently found to be citrullinated in vivo in the synovial fluid. We now show that it is recognized by ACPA as well, thereby adding it to a still selective list of targets. Moreover, we identified an epitope from vinculin recognized by CD4+ T cells restricted to HLA-DQ molecules predisposing to ACPA-positive RA. The core amino acid sequence (DERAA) is also present in many pathogens and in HLA-DRB1*13, a molecule encoded by an HLAlocus associated with protection against ACPA-positive RA. We have also shown that a single TCR can recognize both a vinculin DERAA-epitope as well as DERAAepitopes from microbes, indicating the crossreactive nature of "DERAA"-directed T cell responses. More importantly, such T cell responses appear absent from donors carrying HLA-DRB1*13 as DERAA directed T cell responses to either pathogen-or vinculin-derived DERAA epitopes were lacking in these subjects. Even donors that harbored HLA-DRB1*13 next to predisposing HLA-alleles were unable to respond to vinculin DERAA. Together, these data indicate a novel pathway that explains several of the protective-and predisposing HLA-effects associated with ACPA-positive RA ( Figure  7) . In short, recognition of citrullinated vinculin by B cells will lead to the presentation of the "VCL-DERAA" epitope in the context of HLA class II molecules. The HLA-DQ-molecules genetically linked to the predisposing HLA-SE-molecules are particularly good in presenting DERAA-containing peptides. The DERAA directed T cells primed against various pathogens harboring DERAA-containing proteins cross-react with the VCL-DERAA peptide and provide help to the B cells, ultimately leading to a strong ACPA-response. Subjects born with HLA-DRB1*13, will present the HLA-DRB1*13-derived DERAA-peptide in the thymus, leading to tolerization of the DERAA-reactive T cell response and hence the inability to provide help to ACPA-producing B cells via this pathway and thereby the emergence of ACPA-positive RA (Figure 7) . The variation of HLA-DR and HLA-DQ molecules in the human population is enormous. We have shown that predisposing HLA-DQ molecules are particularly good at presenting the VCL-DERAA epitope. Interestingly, the absence of VCL-DERAA affinity for a wide variety of other tested HLA-DR or HLA-DQ molecules could indicate a selective presentation by these HLA risk-molecules. Next to role of predisposing haplotypes, we also focussed on the protective effect of HLA-DRB1*13 alleles. However, the DERAA sequence can also be found in other HLA-DRB1 alleles (*04:02, *11:02, *11:03), which are rare in Caucasian populations. These alleles have previously been implicated in protection from ACPA+ RA, but their allele frequency hampers functional studies [43] [44] [45] . Interestingly, it has been previously reported that the processing of these alleles results in the generation of a similar HLA-DERAA epitope suggesting that these alleles could all protect via the pathway that we have described [22] . The place in time at which HLA-DR13 mediates protection from the development of ACPA and/or ACPA-positive disease, or its relation to epitope spreading of the ACPA response is currently not known and would be relevant to determine in future studies. Recent evidence showed that the ACPA response matures prior to disease onset and that the HLA system could be involved in this [13, 46] . It is intriguing to DERAA directed T cells are restricted to RA predisposing HLA-DQ5, -DQ7.3 and -DQ8 molecules. In carriers of these HLA-DQ molecules, DERAA directed T cells can become activated upon contact with microbes. These activated T cells can subsequently cross-react with a DERAA epitope derived from vinculin resulting in the activation of citrulline-directed B cells and the production of ACPA directed to citrullinated vinculin or vinculin-linked proteins. Citrullinated vinculin is present in the synovial compartment and is a target of ACPA. Binding of ACPA to its target can induce antibody mediated effector mechanisms thereby contributing to synovial inflammation. In HLA-DRB1*13 positive individuals, a HLA-DRB1*13 derived DERAA epitope is presented by predisposing HLA-DQ molecules to CD4+ T cells resulting in their negative selection, thereby protecting against the development of ACPA-positive RA.
speculate that viral infections such as by DERAA containing microbes are involved in this expansion. Molecular mimicry of self-proteins with pathogenic proteins was proposed as a mechanism to break T cell tolerance, allowing the development of autoimmune disease [26, 27] . Interestingly, the DERAA sequence is also present in proteins from many (common) microbes allowing priming of DERAA directed T cells. In mouse models, it was shown that low-avidity T cells to tissue-restricted antigens can persist without signs of anergy and unresponsiveness. Infection lowers the threshold for T cell activation resulting in the induction of autoimmunity and memory formation [47] . Infection could also induce autoimmunity via molecular mimicry of microbial proteins with self-proteins. We now identified crossreactive epitopes from the gut-residing bacteria L. sakei, L. curvatus and C. coli. It was shown that acute gastrointestinal infections can induce loss of T cell tolerance to (commensal) gut microbes, resulting in the activation of microbiota-specific T cells, their differentiation to inflammatory effector cells, and formation of memory T cells [48] . A recent study on the fecal microbiota of RA patients compared to controls demonstrated a significant increase in Lactobacillus species, together providing a rationale for a role of such bacterial species in the formation of DERAA-directed T cell responses [49] . Together, our study provides a mechanistic clue on the HLA-RA connection, including both predisposing and protective HLA-effect, and warrants further studies addressing the possibility to target DERAA-directed T cells in the prevention of ACPA-positive RA. Table S1 . Figure  Figure S17 . TCR view of the complex of HLA-DQ8 with the VCL-DERAA epitope in the groove at pH 7.4 (extracellular). Depiction and colour conventions as in Figure S16 . Anchors P1V and P9F point into the plane of the paper (screen) and are only partly seen. In vivo, P5R may not interact with P2F (cation-π interaction) because the former might more favorably interact with water molecules from the solvent. Figure S16 . TCR view of the complex of HLA-DQ7.3 with the VCL-DERAA epitope in the groove at pH 7.4 (extracellular). The α1β1 domain of the modelled HLA-DQ molecule is in van der Waals surface representation, colored according to atomic charges (negative = red, positive = blue, neutral = gray, partial charges shades in-between). Several visible residues from the HLA-DQ molecule in contact with the antigenic peptide and potential contact with a cognate TCR in canonical orientation are shown in stick form with a transparent surface (atomic color code: oxygen, red; nitrogen, blue; hydrogen, white; carbon, green; sulfur, yellow). The antigenic peptide in the groove is shown in space-filling form, with identical colour conventions as in Fig. 6d -g. Anchors p1V and p9F point into the plane of the paper (screen) and are only partly seen. In vivo, p5R may not interact with p2F (cation-π interaction) because the former might more favorably interact with water molecules from the solvent. In this allele p4E makes an even weaker anchor than in DQ8, because of β13Gly→Ala and β26Leu→Tyr substitutions (DQ8→DQ7) that leaves less space available at the base of pocket 4. Figure S18 . TCR view of the complex of HLA-DQ8 with the L. curvatus epitope in the groove at pH 7.4 (extracellular). Depiction and colour conventions as in Figure S16 . Anchors P1P and P9F point into the plane of the paper (screen) and are only partly seen. Figure S19 . TCR view of the complex of HLA-DQ8 with the L. sakei epitope in the groove at pH 7.4 (extracellular). Depiction and colour conventions as in Figure S16 . Anchors P1P and P9F point into the plane of the paper (screen) and are only partly seen. Figure S20 . TCR view of the complex of HLA-DQ8 with the C. Coli epitope in the groove at pH 7.4 (extracellular). Depiction and colour conventions as in Figure S16 . Anchors P1F and P9F point into the plane of the paper (screen) and are only partly seen. Table S1 . Statistics of intermolecular hydrogen bonds in the DQ8:VCL-DERAA complex. Hydrogen bonds were considered present if the D -A distance l DA was smaller than 3.5 Å, and the angle θ D-H…A was larger than 150 o . The (*) denotes water-mediated interactions; "sc" and "mc" denote side-chain and main-chain groups.
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